Novartis Cancer Drug Wins Priority Review

Source: Investopedia

Feb 27, 2017

Novartis announced that its lung cancer drug, Zykadia, has secured priority review status from the U.S. FDA for treating patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase-positive.

Zykadia was first approved in April 2014 as a second-line treatment for patients with metastatic ALK-positive NSCLC who were previously treated with Pfizer's Xalkori.

Novartis has claimed, based on the results of a late-stage study, that its drug is twice as effective as chemotherapy in slowing the growth of non-small cell lung cancer.

Read the Investopedia coverage